4-氯-6-环丙基氨基嘧啶 | 941294-43-5

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-6-环丙基氨基嘧啶
• 中文别名: 4-氯-6-环丙氨基嘧啶
• 英文名称: 6-chloro-N-cyclopropylpyrimidin-4-amine
• CAS: 941294-43-5
• 化学式: C₇H₈ClN₃
• 分子量: 169.614
• InChiKey: ZFIQMVQXKPRCGZ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.6±22.0 °C(Predicted)
• 密度：
  1.454

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  存储条件：2-8°C，干燥且密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-6-cyclopropylaminopyrimidine
Synonyms: 6-Chloro-N-cyclopropylpyrimidin-4-amine; 4-Chloro-6-(cyclopropylamino)pyrimidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-6-cyclopropylaminopyrimidine
CAS number: 941294-43-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8ClN3
Molecular weight: 169.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-环丙基氨基嘧啶 在 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 氢气 、 sodium hydride 、 caesium carbonate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.0h， 生成 N-(2-((6-(1-cyclopropyl-3-(2,6-dichloro-3,5-dimethoxyphenyl)ureido)pyrimidin-4-yl)amino)5-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide
  参考文献：
  名称：

  嘧啶类衍生物及其制备方法和其在医药上的 用途

  摘要：

  本发明涉及嘧啶类衍生物及其制备方法和医药用途。具体而言，本发明涉及一种通式(I)所示的嘧啶类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是作为FGFR4激酶抑制剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。

  公开号：

  CN107400092B
• 作为产物：
  描述：

  4,6-二氯嘧啶 、 环丙胺 以 异丙醇 为溶剂， 反应 4.0h， 以16.7%的产率得到4-氯-6-环丙基氨基嘧啶
  参考文献：
  名称：

  嘧啶类衍生物及其制备方法和其在医药上的 用途

  摘要：

  本发明涉及嘧啶类衍生物及其制备方法和医药用途。具体而言，本发明涉及一种通式(I)所示的嘧啶类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是作为FGFR4激酶抑制剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。

  公开号：

  CN107400092B

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050200A1

  公开（公告）日：2011-04-28

  Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和症状的方法中有用，比如失眠。
• Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders
  作者：Satoru Noji、Yoshinori Hara、Tomoya Miura、Hiroshi Yamanaka、Katsuya Maeda、Akimi Hori、Hiroshi Yamamoto、Shingo Obika、Masafumi Inoue、Yasunori Hase、Takuya Orita、Satoki Doi、Tsuyoshi Adachi、Atsuo Tanimoto、Chika Oki、Yukari Kimoto、Yoshihiro Ogawa、Tamotsu Negoro、Hiromasa Hashimoto、Makoto Shiozaki

  DOI：10.1021/acs.jmedchem.0c00450

  日期：2020.7.9

  display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models

  诸如特应性皮炎的皮肤疾病源于遗传和环境原因，并且本质上是复杂的和多因素的。在可能的危险因素中，异常的免疫反应是主要病因之一。包括局部类固醇在内的免疫抑制剂是这些疾病的常见治疗方法。尽管它们在临床环境中具有可靠性，但局部类固醇仍具有副作用，典型表现为皮肤变薄。因此，需要替代的有效和良好耐受的疗法。作为研究新的免疫调节剂的努力的一部分，我们开发了一系列JAK抑制剂，这些抑制剂结合了新颖的三维螺旋基序，并且出乎意料地在动物模型中拥有出色的理化特性和抗皮炎功效。其中一种化合物JTE-052（ent - 60，也称为delgocitinib，在人体临床试验中已显示出有效且耐受性良好，最近在日本被批准用于治疗特应性皮炎，是Janus激酶抑制剂中的第一种药物。
• FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS
  申请人：Branstetter Bryan James

  公开号：US20120202783A1

  公开（公告）日：2012-08-09

  Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了双取代的3,8-二氮杂-四环[4.2.0]辛烷和3,6-二氮杂-三环[3.2.0]庚烷化合物，可用作促进荷尔蒙受体的调节剂。这些化合物可用于制备药物组合物和治疗由荷尔蒙活性介导的疾病状态、紊乱和情况，如失眠。
• Fused heterocyclic compounds as orexin receptor modulators
  申请人：Branstetter Bryan James

  公开号：US08680275B2

  公开（公告）日：2014-03-25

  Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了二取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷化合物，这些化合物可用作促进荷尔蒙受体的调节剂。这些化合物可用于制备药物组合物和治疗因荷尔蒙活性介导的疾病状态、障碍和病况，如失眠。
• [EN] HETEROCYCLIC COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE ET SON APPLICATION<br/>[ZH] 一种杂环化合物及其应用
  申请人：SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD

  公开号：WO2021018226A1

  公开（公告）日：2021-02-04

  一种具备式I所示结构的杂环化合物及其应用。实验结果表明，所述杂环化合物具备甲状腺激素β受体激动活性，可用于治疗和/或预防由甲状腺激素调节引起的疾病。